Market Overview

UPDATE: BMO Capital Markets Initiates Abbott Laboratories at Outperform on Growth, Margin Expansion

Share:
Related ABT
Wide Moat ETF Is On A Tear
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Abbott Laboratories: Should I Stay Or Should I Go? (Seeking Alpha)

BMO Capital Markets initiated coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating and a $36 price target.

BMO Capital Markets noted, "The new Abbott is expected to deliver 2012E sales of $21.5B (flat; up 4% ex-FX) from four distinct businesses: Nutritionals (30% of sales); Medical Products (26%); Established Pharmaceuticals (24%); and Diagnostics (20%). With leading market share positions and an extensive geographic footprint, particularly in the emerging markets (about 40% of revenue), we expect the company to benefit from a focused management team and dedicated resources, to drive mid- to high-single-digit revenue growth, expand operating margins, and deliver double-digit EPS."

Abbott Laboratories closed at $31.40 on Monday.

Latest Ratings for ABT

DateFirmActionFromTo
Apr 2016Piper JaffrayDowngradesOverweightNeutral
Mar 2016JefferiesMaintainsBuy
Feb 2016Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!